Paper36588698
Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling.
Grañana-Castillo S and 4 others. Front Pharmacol, 2022. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling. Papers, record 36588698. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36588698
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32638292 | Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis. | Int J Clin Pharm | 2020 | https://conductscience.org/library/papers/32638292 | PubMed |
| 2 | 34822220 | Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. | J Int AIDS Soc | 2021 | https://conductscience.org/library/papers/34822220 | PubMed |
| 3 | 18775982 | Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. | Drug Metab Dispos | 2008 | https://conductscience.org/library/papers/18775982 | PubMed |
| 4 | 32240629 | Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. | Lancet HIV | 2020 | https://conductscience.org/library/papers/32240629 | PubMed |
| 5 | 11158730 | Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. | Antimicrob Agents Chemother | 2001 | https://conductscience.org/library/papers/11158730 | PubMed |
| 6 | 22096405 | Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. | HIV AIDS (Auckl) | 2011 | https://conductscience.org/library/papers/22096405 | PubMed |
| 7 | 33609656 | Pyridones in drug discovery: Recent advances. | Bioorg Med Chem Lett | 2021 | https://conductscience.org/library/papers/33609656 | PubMed |
| 8 | 32816220 | Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. | Clin Drug Investig | 2020 | https://conductscience.org/library/papers/32816220 | PubMed |
| 9 | 26201299 | Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. | Lancet Infect Dis | 2015 | https://conductscience.org/library/papers/26201299 | PubMed |
| 10 | 12885263 | Whole body pharmacokinetic models. | Clin Pharmacokinet | 2003 | https://conductscience.org/library/papers/12885263 | PubMed |
| 11 | 11868802 | Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. | Eur J Clin Pharmacol | 2002 | https://conductscience.org/library/papers/11868802 | PubMed |
| 12 | 19307295 | Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. | Drug Metab Dispos | 2009 | https://conductscience.org/library/papers/19307295 | PubMed |
| 13 | 24060875 | Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/24060875 | PubMed |
| 14 | 35943252 | Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/35943252 | PubMed |
| 15 | 33951360 | Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33951360 | PubMed |
| 16 | 20368326 | Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. | Drug Metab Dispos | 2010 | https://conductscience.org/library/papers/20368326 | PubMed |
| 17 | 27799217 | Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/27799217 | PubMed |
| 18 | 24614383 | Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/24614383 | PubMed |
| 19 | 33541517 | Anthropometric Reference Data for Children and Adults: United States, 2015-2018. | Vital Health Stat 3 | 2021 | https://conductscience.org/library/papers/33541517 | PubMed |
| 20 | 26380154 | Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers. | CPT Pharmacometrics Syst Pharmacol | 2015 | https://conductscience.org/library/papers/26380154 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41658591 | A clinically significant interaction between voriconazole and rifapentine: a case report and review of evidence. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/41658591 | PubMed |
| 40968422 | Application of Physiologically Based Pharmacokinetic Modeling in the Research of Anti-HIV Drugs. | Curr Drug Metab | 2025 | https://conductscience.org/library/papers/40968422 | PubMed |
| 40733576 | The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections. | Viruses | 2025 | https://conductscience.org/library/papers/40733576 | PubMed |
| 40560789 | Development and hepatotoxicity of rifamycin derivatives. | Expert Opin Drug Metab Toxicol | 2025 | https://conductscience.org/library/papers/40560789 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AADAC | 13 | PubTator's text mining | https://conductscience.org/library/genes/13 | NCBI Gene |
| ABCB1 | 5243 | PubTator's text mining | https://conductscience.org/library/genes/5243 | NCBI Gene |
| CYP2B6 | 1555 | PubTator's text mining | https://conductscience.org/library/genes/1555 | NCBI Gene |
| CYP3A4 | 1576 | PubTator's text mining | https://conductscience.org/library/genes/1576 | NCBI Gene |
| SLCO1B1 | 10599 | PubTator's text mining | https://conductscience.org/library/genes/10599 | NCBI Gene |
| SLCO1B3 | 28234 | PubTator's text mining | https://conductscience.org/library/genes/28234 | NCBI Gene |
| UGT1A1 | 54658 | PubTator's text mining | https://conductscience.org/library/genes/54658 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36588698
GET https://conductscience.org/api/papers/v1/36588698/references?page=2